Related Experiment Video
Updated: Jul 4, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Biosimilars: illustration of scientific issues in two examples
1Diamond Headache Clinic Inpatient Unit, St. Joseph Hospital, 2900 North Lake Shore Drive, Chicago, IL 60657, USA. rwenz@hotmail.com
Summary
Biosimilars, like botulinum neurotoxins and erythropoietic agents, present clinical challenges. Differences in characteristics and reimbursement require careful consideration for effective patient care and product selection.
Area of Science:
- Pharmacology
- Biopharmaceuticals
- Clinical Medicine
Background:
- Biosimilars are biopharmaceuticals highly similar to innovator products, with minor allowable differences.
- Understanding scientific and clinical implications is crucial for their effective use.
Purpose of the Study:
- To illustrate scientific issues and clinical implications of biosimilars using botulinum neurotoxins and erythropoietic agents as examples.
- To highlight differences between biosimilar products and their innovator counterparts.
Main Methods:
- Comparative analysis of botulinum neurotoxin products (Botox and Dysport).
- Examination of ethical and practical considerations for erythropoietic agents.
- Review of regulatory and clinical trial requirements for biosimilar approval.
Main Results:
- Botulinum toxin type A products exhibit distinct differences in physicochemical properties, indications, dosing, and adverse event profiles.
- Reimbursement policies for erythropoietic agents vary, impacting patient access and treatment optimization.
- Establishing consistent, valid criteria for comparing biosimilar and innovator product efficacy and safety is essential.
Conclusions:
- Biosimilar use involves complexities including product variability, reimbursement challenges, and the need for robust comparative data.
- Pharmacists can contribute to data collection on immunogenicity for botulinum neurotoxin products.
- Future regulatory definitions for biosimilar erythropoietic agents' efficacy and equivalence are pending.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...